2 weeks Ago By ABMN Staff
Affimed ( NASDAQ:AFMD – Get Free Report ) will issue its quarterly earnings data before the market opens on Thursday, November 14th. Analysts expect the company to announce earnings of ($1.14) per share for the quarter.
Investors interested in registering for the company’s conference call can do so using this link . Affimed ( NASDAQ:AFMD – Get Free Report ) last released its earnings results on Thursday, September 5th. The biopharmaceutical company reported ($1.
09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.00) by ($0.09).
The business had revenue of $0.17 million for the quarter, compared to analysts’ expectations of $1.67 million.
Affimed had a negative return on equity of 155.30% and a negative net margin of 2,922.74%.
On average, analysts expect Affimed to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year. Affimed Stock Performance Shares of AFMD opened at $3.76 on Wednesday.
Affimed has a 12-month low of $2.92 and a 12-month high of $8.95.
The company has a debt-to-equity ratio of 0.13, a current ratio of 2.71 and a quick ratio of 2.
71. The business’s 50 day moving average is $3.50 and its 200 day moving average is $4.
55. Analyst Upgrades and Downgrades Read Our Latest Stock Analysis on AFMD Affimed Company Profile ( Get Free Report ) Affimed N.V.
, a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. Featured Stories Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.
com's FREE daily email newsletter ..
